
Foghorn Therapeutics Inc.: updates and filings
Price
$1.79
November 16, 2026Market cap $105M
What Ploutos Investor adds for Foghorn Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 6 fiscal years, from 2020
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- Profit over the last twelve months is well above what the business itself earned, because it includes large gains outside the business, such as on investments or from selling a business. The P/E is lower than the business alone would give.
- Earnings per share here are the last twelve months' earnings over today's shares, so they agree with the P/E. The number of shares changed a lot during the year, so they differ from the earnings per share the company filed, which use the year's average number of shares.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 9, 2026next Feb 5, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
August 2026
May 2026
March 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 9, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 9, 2026Results of operations, Regulation FD disclosureForm8-K
- Oct 5, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Oct 1, 2026Restructuring costs, Regulation FD disclosureForm8-K
- Aug 6, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 6, 2026Results of operations, Regulation FD disclosureForm8-K
- Jun 24, 2026Shareholder voteForm8-K
- May 15, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 7, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 7, 2026Results of operations, Regulation FD disclosureForm8-K
- May 6, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Apr 30, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 30, 2026Additional annual meeting materialFormDEFA14A
- Apr 30, 2026Annual meeting proxy statementFormDEF 14A
- Apr 21, 2026Regulation FD disclosure, other material eventsForm8-K
- Mar 26, 2026Shares registered for employeesFormS-8
- Mar 11, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Mar 11, 2026Results of operations, Regulation FD disclosureForm8-K
- Feb 23, 2026Officer or director change, other material eventsForm8-K
- Jan 13, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Jan 12, 2026Results of operations, Regulation FD disclosure, other material eventsForm8-K
- Dec 4, 2025Officer or director changeForm8-K
- Nov 7, 2025Regulation FD disclosureForm8-K
- Nov 5, 2025Quarterly reportfor the period to Sep 30, 2025Form10-Q
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 9, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 9, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Oct 5, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Oct 1, 2026 | 8-K | Restructuring costs, Regulation FD disclosure | Document |
| Aug 6, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 6, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Jun 24, 2026 | 8-K | Shareholder vote | Document |
| May 15, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 7, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 7, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| May 6, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Apr 30, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 30, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 30, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Apr 21, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Mar 26, 2026 | S-8 | Shares registered for employees | Document |
| Mar 11, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Mar 11, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Feb 23, 2026 | 8-K | Officer or director change, other material events | Document |
| Jan 13, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Jan 12, 2026 | 8-K | Results of operations, Regulation FD disclosure, other material events | Document |
| Dec 4, 2025 | 8-K | Officer or director change | Document |
| Nov 7, 2025 | 8-K | Regulation FD disclosure | Document |
| Nov 5, 2025 | 10-Q | Quarterly reportfor the period to Sep 30, 2025 | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Aug 28, 2020.
The full analysis
What do Foghorn Therapeutics's filings show?
The filings are where every one of Foghorn Therapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.